I frankly am more concerned with establishing a staff of top notch scientists, if the management can keep such a team together and keep them funded, I can live with what many call bad management.
I believe the difference between investor's loving and hating management is success. When just one of their drugs is approved and earning substantial money, these manager's will suddenly become geniuses.
I've been involved with IMGN for decades, I can't say it's been a success, but they've held a teem of scientists together and right now about 15 of the 60 conjugate drugs in clinical trials are using their technology. I believe their future is quite bright, and we're starting to see it in the share price. Their first CEO would discuss things happening soon, but they took so long that investor's spell it backwards when quoting him. What I can say about him was that what he said would happen eventually did happen, what was soon to him was months to years to us. He's not been part of the company for many year's, yet the team he put together is largely responsible for the success that seems to be occurring now.
I've not been with this company long enough to really have an opinion about the management, I bought in because I liked the science, and if the management has put together and held together the scientists who created the technology, I can't get too excited about how they've treated stockholders.
Gary
News 
Market Data 
Discover 
